Mike is a General Partner of S32, a venture capital firm investing at the frontiers of technology. Prior to joining S32 in 2017, he served as CEO of Foundation Medicine, a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to Chairman through the close of Roche’s (RHHBY) acquisition of FMI in August 2018. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010.

‍

He currently serves on the Board of Directors for Nusano, Octave BioSciences, TwinStrand Genomics, Exai Bio, and Delve Bio. He previously served on the Board of the American Cancer Society until July 2025, as well as on the boards of Thrive Earlier Detection—acquired by Exact Sciences (EXACT) in 2021, Tango Therapeutics (TNGX), Adaptive Biotechnologies (ADPT), and Singular Genomics (OMIC). Mike brings deep expertise in personalized medicine, with a particular passion and focus on defeating cancer.

‍

During the COVID  pandemic, Mike served as a Senior Advisor to the Rockefeller Foundation’s efforts on COVID-19 testing.

‍

Mike received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.